Balaxi Pharmaceuticals Board of Directors

Get the latest insights into the leadership at Balaxi Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Ashish Maheshwari Managing Director
Mrs. Minoshi Maheshwari Non Executive Director
Ms. Akshita Surana Independent Director
Mr. Mangina Srinivas Rao Independent Director
Mr. Gandhi Gamji Independent Director
Mr. Kunal Mahendra Bhakta Independent Director

Balaxi Pharmaceuticals Share price

BALAXI

41.12

0.85 (-2.03%)
Last updated on 17 Oct, 2025 | 15:46 IST
BUYSELL
Today's High

42.50

Today's Low

40.76

52 Week Low

40.76

52 Week High

98.94

The current prices are delayed, login to your account for live prices

Balaxi Pharmaceuticals FAQs

The board at Balaxi Pharmaceuticals consists of experienced professionals, including Mr. Ashish Maheshwari , Mrs. Minoshi Maheshwari , and others, overseeing the company’s strategic and corporate governance.

Directors at Balaxi Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Ashish Maheshwari is the current chairman at Balaxi Pharmaceuticals.

Executive directors at Balaxi Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Balaxi Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Balaxi Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.